Previous 10 | Next 10 |
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX ® , its investigatio...
FUROSCIX ® is currently under development for the treatment of congestion due to fluid overload in adult patients with worsening heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization Call on Tuesday, September 29, 2020 at 11am E...
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two ...
ScPharmaceuticals (NASDAQ: SCPH ) perks 10% premarket after entering into a supply agreement with West Pharmaceutical Services (NYSE: WST ) , pursuant to which the Company has agreed to purchase the SmartDose drug delivery system developed by West (the Product). More news ...
scPharmaceuticals (NASDAQ: SCPH ) : Q2 GAAP EPS of -$0.39 beats by $0.03 . More news on: scPharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Preparations ongoing for December 30, 2020 FUROSCIX ® PDUFA date scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and red...
The FDA has accepted for review scPharmaceuticals' (NASDAQ: SCPH ) resubmitted marketing application seeking approval of Furoscix (furosemide), administered via subcutaneous infusion via a pre-programmed on-body drug delivery system, for the treatment of worsening heart failure due to co...
FDA sets PDUFA date of December 30, 2020 scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Sara Bonstein to its ...
Rebounding from the Complete Response Letter (CRL) it received in June 2018, scPharmaceuticals (NASDAQ: SCPH ) has resubmitted its U.S. marketing application seeking approval of Furoscix (subcutaneous furosemide) for the treatment of congestion in heart failure patients. More news...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...